2186 — Luye Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapValue Trap

Annual income statement for Luye Pharma, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	6,358	5,540	5,200	5,982	6,143
Cost of Revenue
Gross Profit	4,879	3,991	3,397	4,141	4,204
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	4,430	4,175	4,876	4,841	4,768
Operating Profit	1,928	1,364	324	1,141	1,375
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,634	942	-74.6	670	700
Provision for Income Taxes
Net Income After Taxes	1,354	703	-145	583	539
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,396	707	-134	605	533
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,396	707	-134	605	533
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.431	0.221	0.01	0.191	0.145
Dividends per Share